More than 1 in 4 adults have 1 or more conditions that fall into the cardio-renal-metabolic category, according to findings released during Kidney Week 2022.
A poster presented during Kidney Week 2022 examined the characteristics of cardio-renal-metabolic (CRM) conditions and their overlap with each other, as well as the most commonly used treatments.
CRM conditions were defined as cardiovascular disease (CVD), atherosclerotic CVD or heart failure, chronic kidney disease (CKD), or type 2 diabetes (T2D). Dysfunctions in the cardiac, kidney, and metabolic systems are increasingly being recognized as intertwined, requiring multidisciplinary strategies. Shared risk factors for all of these disease include obesity, hypertension, dysglycemia, and dyslipidemia.
Separately, diseases of these 3 systems represent leading causes of death, disability, and economic burden and are prevalent throughout the US population, but the frequency with which they coexist has not been extensively characterized, researchers said.
Researchers used cross-sectional data from the 2015-2018 National Health and Nutrition Examination Survey (NHANES), evaluating nonpregnant US adults aged ≥ 20 years. They calculated weighted proportion of participants with CRM conditions, both overall and stratified by age. They also evaluated the use of CRM drug therapies.
The analysis included an unweighted sample of 9113 US adults (mean age 48.3 years; 51.0% women). Applying population weights, the authors said 27.6% of US adults (about 70 million adults) had ≥ 1 CRM condition, 8.7% had ≥ 2 CRM conditions, and 1.5% had all 3 CRM conditions.
Individually, CVD was seen in 10.1% of participants, CKD in 14.7%, and T2D in 13.1%. CKD and T2D was the most common CRM dyad (3.2%), followed by CVD and CKD (2.1%), and CVD and T2D (1.9%).
By age, of those ≥65 years, 59.1% had ≥1 CRM condition, 24.5% had ≥2, and 4.9% had 3 CRM conditions. In the older age group, CVD and CKD (8.2%) was most common, followed by CKD and T2D (7.4%), and CVD and T2D (4.0%).
Higher CRM comorbidity burden was linked with more severe CKD stage, additive CVD conditions, older age, male sex, Black race, greater prevalence of key CRM risk factors, and poor socioeconomic characteristics.
Among individuals with all 3 CRM conditions, researchers found:
The authors noted that the study had several limitations, such as NHANES represents data from individuals living in the community and may not be applicable to other settings. But they called use of CRM therapies “suboptimal.”
The study was funded by Boehringer Ingelheim Pharmaceuticals.
Reference
Ostrominski JW, Arnold SV, Butler J, et al. Prevalence and overlap of cardio-renal-metabolic conditions in US adults, 2015-2018. Presented at: Kidney Week 2022; November 3-6, 2022; Orlando, Florida. Abstract TH-PO601.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More